Rachel H. Goode

Dec 14, 2023 | jamanetwork.com | S. Tu |Rachel H. Goode |Fresenius Kabi USA

Spending on biologics in 2021 represented $260 billion or 46% of all spending on prescription drugs in the US.1 Biosimilar competition can lower prices, but biosimilar entry is often delayed by expansive patent thickets (dozens or hundreds of patents directed toward the same product).

Nov 13, 2023 | jamanetwork.com | Rachel H. Goode |Fresenius Kabi USA |William B. Feldman |S. Tu

In 2021, 46% ($260 billion) of all gross prescription drug spending in the US was on biologic products.1 Patents are government-granted monopolies that last 20 years; by obtaining multiple patents for different aspects of the same product, biologic manufacturers create “patent thickets” that can block or delay biosimilar competition to protect market share.2,3 Although patent gamesmanship by biologic manufacturers has been well documented, a key strategy that has not received sufficient...